Z Squared (ZSQR) Registration filing summary
Event summary combining transcript, slides, and related documents.
Registration filing summary
26 Jun, 2026Company overview and business model
Operates as a computing and digital infrastructure company, primarily focused on Dogecoin and Litecoin mining using Scrypt-algorithm ASIC hardware across six facilities in North Carolina, South Carolina, and Iowa.
Pursuing expansion into AI, high-density compute, data center development, and power generation, targeting 100 MW of AI-ready inference capacity over 18 months via an acquire-and-convert strategy.
Mining fleet consists of 9,800 ASIC miners acquired from BSG Series CM, LLC as part of a business combination completed in April 2026.
Financial performance and metrics
As of March 31, 2026, reported an accumulated deficit of approximately $113.9 million and a net loss of $4.0 million for the three months then ended.
Historical financials reflect OpCo as the accounting acquirer; prior to the business combination, OpCo was a development-stage enterprise with minimal revenue.
Substantial doubt exists about the ability to continue as a going concern, with significant additional capital required for operations and fleet deployment.
Use of proceeds and capital allocation
Will not receive any proceeds from the resale of shares by selling securityholders; all proceeds go to the selling securityholders.
Company will bear registration and listing costs, while selling securityholders pay commissions and related sale expenses.
Latest events from Z Squared
- Cell therapy and AI platform developer faces ongoing losses but secures $30M in new funding.ZSQR
Registration filing26 Jun 2026 - Net loss narrowed, but ongoing losses and liquidity risks persist despite new capital raised.ZSQR
Q4 202426 Jun 2026 - Net loss narrowed, expenses declined, and $4.3M was raised in Series A Preferred Stock.ZSQR
Q2 202426 Jun 2026 - Net loss narrowed, expenses fell, and $5.8M was raised, but going concern risks persist.ZSQR
Q3 202426 Jun 2026 - 2025 revenue growth in technology offset by biotech losses; net loss $12.28M, merger pending.ZSQR
Q4 202526 Jun 2026 - Biopharma firm registers 3.9M shares for resale to fund R&D amid ongoing losses and high risk.ZSQR
Registration filing26 Jun 2026 - Biopharma firm seeks to commercialize novel cell therapies amid financial and listing challenges.ZSQR
Registration filing26 Jun 2026 - Net loss widened to $3.4M in Q1 2025 despite increased cash and new financing initiatives.ZSQR
Q1 202526 Jun 2026 - Proxy seeks approval for director elections, reverse split, $20M equity deal, and executive pay.ZSQR
Proxy filing26 Jun 2026